Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Boehringer Ingelheim
Chinese Patent Office
Cantor Fitzgerald
Moodys
Accenture
McKesson
US Department of Justice
Cipla

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,096,339

« Back to Dashboard

Which drugs does patent 6,096,339 protect, and when does it expire?

Patent 6,096,339 protects COVERA-HS and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 6,096,339
Title: Dosage form, process of making and using same
Abstract:The invention disclosed pertains to a dosage form comprising an agent formulation comprising drug and pharmaceutical carrier of cooperating particle size and means for dispensing the agent formulation from the dosage form.
Inventor(s): Ayer; Atul D. (Palo Alto, CA), Lam; Andrew (San Francisco, CA), Magruder; Judy A. (Mountain View, CA), Hamel; Lawrence G. (Mountain View, CA), Wong; Patrick S. L. (Palo Alto, CA)
Assignee: ALZA Corporation (Mountain View, CA)
Application Number:08/826,642
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Process; Delivery; Use;

Drugs Protected by US Patent 6,096,339

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 DISCN No No ➤ Subscribe ➤ Subscribe METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 DISCN No No ➤ Subscribe ➤ Subscribe METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,096,339

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,096,339

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 9737640 ➤ Subscribe
Portugal 907358 ➤ Subscribe
New Zealand 332014 ➤ Subscribe
Japan 4262776 ➤ Subscribe
South Korea 20000005230 ➤ Subscribe
Japan 2000508313 ➤ Subscribe
Hong Kong 1020523 ➤ Subscribe
Spain 2166988 ➤ Subscribe
European Patent Office 0907358 ➤ Subscribe
Denmark 0907358 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Argus Health
Merck
Citi
AstraZeneca
Fish and Richardson
Baxter
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot